← Back to Nuqta Atlas
Editorially curated · sa-kfshrc-clinical-pgx
KFSHRC Clinical Pharmacogenomics Program
Integrates germline pharmacogenetic testing and clinical decision support into prescribing across multiple specialties.
01 / Project overview
What the record establishes.
- Geographic scope
- KFSHRC patients, initially cardiology and neurology and later transplant and other specialties
- Project type
- Clinical precision-prescribing implementation program
- Research domain
- Pharmacogenomics
- Years
- 2023–
- Lifecycle status
- active
- Status basis
- Launched in September/October 2023; KFSHRC reported more than 1,500 patients analyzed and continued specialty expansion in October 2024.
- Status evidence date
- 2024-10-01
- Scale
- More than 1,500 patients by October 2024; over 70% carried altered function in at least three genes. Initial phase covered six medicines and later expanded.
02 / Organizations and population
Who and what the project connects.
- Lead organizations
- King Faisal Specialist Hospital & Research Centre (KFSHRC)
- Partner organizations
- Not stated
- Organism / population
- Saudi and national-referral KFSHRC patients receiving genotype-guided medicines
03 / Data and access
What exists and how it can be reached.
Data types
- pharmacogenetic testing
- EHR clinical decision support
- medication outcomes
Data access
Clinical service; individual data controlled
Identifiers
No public accession or identifier is listed for this record.
04 / Evidence and provenance
Why the record is included.
Inclusion basis
Operational clinical-genomics implementation program with an explicit patient scale and prescribing integration.
Editorial note
Distinct from the SHGP population-frequency pharmacogenomics cohort; included under KFSHRC's broader Genomic Medicine Center umbrella.
Sources
- primary record source Verified 2026-08-15
- additional record source Verified 2026-08-15
Release v0.2.0